Company Overview and News

8
Will compulsory delivery impact F&O trading?

2018-06-29 thehindubusinessline
KS Badri Narayanan Be prepared to have enough money in your account if you want to trade in the 46 F&O stocks that have been moved to the compulsory delivery category by the NSE starting July. This follows the SEBI diktat in March to align the cash and derivative segments of the market, through physical settlement for all stock derivatives in a phased and calibrated manner. To start with, the NSE has initiated compulsory delivery in 46 stocks.
SRI 532939 SREINFRA GODREJIND 533096 UBL IDBI 532899 532712 532478 533106 JUSTDIAL GRANULES 535648 RCOM OIL 532482 KSCL DCBBANK RPOWER SIFLY 523756 ALNSE 500116 UBHOLDINGS 535322 SRIA UNBWY REPCOHOME 532772 ADANIPOWER 507458 500164 JSTQY

37
Market Live: Sensex, Nifty continue to trade lower; Tech Mahindra, Titan top losers

2018-06-28 moneycontrol
Capacite Infraprojects bags order: Capacite Infraprojects has received repeat order worth Rs 190.90 crore (excluding GST & value of free issue materials i.e. re-inforcement Steel and concrete) for construction of rehab building on turnkey basis from Sheth Creators as per finishing matrix including Civil-RCC, block works, plaster works, water proofing, finishing works, electrical, plumbing, and fuefighting work etc.
INDIANB 500325 533096 KAJARIACER HCTHY TCHQY 531548 532755 511218 532483 SRRQY 532480 532281 BJJQY RLNIY ASHOKLEY EXIDEIND TATAPOWER ALBK JETAIRWAYS APOLLOTYRE AYRQY AKLD JSWSTEEL CNRYY TECHM EXQDY BAJFINANCE TATASTEEL FORTIS TATLY HCLTECH 500180 KOTAKBANK CANBK AKLS SOMANYCERA 500228 RELIANCE 532617 532814 KTKBANK SRTRANSFIN 533106 500470 532187 OIL RIGD 500233 HDFCBANK 500477 500034 HINDALCO INDUSINDBK KMBKY 500877 IBN 532843 532652 HNDNF ICICIBANK TTST HDB 532174 TPCL 500400 ADANIPOWER 500247 500086 500440

13
Market Live: Sensex trades higher, Nifty inches towards 10,800; RIL, ICICI Bank dip

2018-06-26 moneycontrol
Piramal Enterprises sells stake in subsidiary company: Piramal Enterprises' subsidiary has divested its entire stake in Piramal Imaging SA to UK's Alliance Medical Acquisitionco.
500408 500325 AUROPHARMA 590003 RELIANCE 512573 PRMQY 533106 OIL JMCPROJECT RIGD 522263 RLNIY AVANTI 524804 KMBKY IBN PEL ICICIBANK 532210 532174 ARBQY CUB KOTAKBANK TATAELXSI 500302 500247 KARURVYSYA

2
Oil India gains 1% on hydrocarbon discovery in KG Basin, Andhra Pradesh

2018-06-26 moneycontrol
Shares of Oil India rose 1.5 percent intraday Tuesday as company made hydrocarbon discovery in KG Basin, Andhra Pradesh.
533106 OIL

5
Will new discovery fuel Oil India shares?

2018-06-25 thehindubusinessline
Oil India has made its second hydrocarbon discovery in the onland KG Basin NELP VI Block in May 2018 at well Thanelanka-l in Andhra Pradesh.
533106 OIL 500570 TATAMOTORS TTM

2
Oil India Limited - Press Release

2018-06-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533106 OIL

3
Timely execution of Central projects critical to North East economic development: Vijay Goel

2018-06-21 freepressjournal.in
Guwahati: Timely execution of central projects in the North East was critical for the overall economic and social development of the region, Union Minister of state for Statistics and Programme Implementation Vijay Goel said here today.
533106 OIL KMBKY KOTAKBANK 500247

7
Centre looks to sell 10% stake in Oil India

2018-06-20 freepressjournal.in
New Delhi : The government is planning to divest up to 10 per cent stake in Oil India (OIL) in 2018-19, a senior finance ministry official said.
533106 OIL CLNDY 533278 COALINDIA

17
Bharat-22 ETF: Anchor investors put in Rs 5,163 cr bids, subscribe 3.44 times

2018-06-19 moneycontrol
The second tranche of Bharat-22 ETF follow-on offer was lapped up by institutional investors today, with the portion reserved for anchor bidders getting subscribed 3.44 times to the tune of Rs 5,163 crore.
INDIANB BHQRY AXB 532814 533278 532215 AXBKY 533106 AXBA 532178 OIL AXISBANK ENGINERSIN 500049 BEL CLNDY COALINDIA

3
HPCL, Oil India to set up joint venture for city gas distribution

2018-06-14 livemint
Mumbai: State-run Hindustan Petroleum Corp. Ltd (HPCL) and exploration and production company Oil India Ltd will shortly form a city gas distribution joint venture (JV), said two people aware of the development.
533106 OIL HINDPETRO 500104

17
Second tranche of Bharat-22 ETF on June 19; govt to get up to Rs 8,400 cr

2018-06-13 moneycontrol
The Finance Ministry will launch the second tranche of Bharat-22 exchange traded fund (ETF) on June 19 which will help raise up to Rs 8,400 crore from the markets. The issue will open for anchor investors on June 19 and for other institutional and retail investors the next day. The ETF follow on offer will remain open till June 22.
INDIANB BHQRY AXB 532814 533278 532215 AXBKY 533106 AXBA 532178 OIL AXISBANK ENGINERSIN 500049 BEL CLNDY COALINDIA

17
Second tranche of Bharat-22 ETF on June 19; govt to get up to Rs 8,400 cr

2018-06-13 thehindubusinessline
The Finance Ministry will launch the second tranche of Bharat-22 exchange traded fund (ETF) on June 19 which will help raise up to ₹8,400 crore from the markets.
INDIANB BHQRY AXB 532814 533278 532215 AXBKY 533106 AXBA 532178 OIL AXISBANK ENGINERSIN 500049 BEL CLNDY COALINDIA

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

12h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...